Table 3.
Change from baseline.
| SP | PAA | p-value | |
|---|---|---|---|
| IPSS | |||
| Total | −3.8 ± 5.3 | −6.1 ± 4.8 | 0.536 |
| Storage | −1.7 ± 2.6 | −3.1 ± 2.6 | 0.414 |
| Voiding | −2.1 ± 3.8 | −2.7 ± 3.0 | 0.804 |
| QOL | −0.8 ± 1.4 | −0.9 ± 1.6 | 0.805 |
| OABSS | −1.2 ± 2.6 | −1.9 ± 2.8 | 0.724 |
| IIEF5 | 0.2 ± 0.5 | 0.9 ± 1.1 | 0.047 |
| ICIQ-SF | −0.9 ± 3.8 | −2.4 ± 4.7 | 0.564 |
| UFM | |||
| RV (ml) | 0.5 ± 44.0 | −1.4 ± 31.1 | 0.892 |
| Qmax (ml/s) | −1.0 ± 5.3 | −0.3 ± 7.0 | 0.703 |
| 8-OHdG (ng/mlCRE) | −1.0 ± 5.4 | 2.3 ± 5.7 | 0.232 |
Notes: IPSS, International prostate symptom score; QOL, quality of life; OABSS, Overactive Bladder Symptom Score; IIEF5, 5-item version of the International Index of Erectile Function; ICIQ-SF, Consultation on Incontinence Questionnaire e-short Form; UFM, uroflowmetry; RV, residual urine volume; Qmax, maximum flow rate; 8OHdG, 8-hydroxy-2′-deoxyguanosine.